# Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer

- Source: PR Newswire
- Published: 2026-10-21T12:43:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/geneos-therapeutics-initiates-impact31-phase-2-randomized-clinical-trial-evaluating-neoantigen-targeted-personalized-dna-immunotherapy-for-cancer-302915471.html
- Canonical: https://groundlevelnews.com/story/geneos-therapeutics-initiates-impact31-phase-2-randomized-clinical-tri-30471a/

The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._